{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:10:08Z","timestamp":1779894608972,"version":"3.53.1"},"reference-count":39,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In recent randomized trials, omitting consolidative radiotherapy (RT) in early-stage Hodgkin lymphoma (ESHL) increased relapses. However, decades of follow-up are required to observe whether lower initial disease control is compensated by reduced risk of late effects. Extrapolation beyond trial follow-up is therefore necessary to inform current treatment decisions. To this end, we developed a microsimulation model to estimate lifetime quality-adjusted life years (QALYs) after combined modality treatment (CMT) or chemotherapy-alone for stage I\/IIa ESHL. For CMT, the model included risks of breast and lung cancer, coronary heart disease, and ischemic stroke. Comparative outcomes were assessed for a clinically relevant range of example patients differing by age, sex, smoking status, and representative organs at risk (OAR) radiation doses informed by the RAPID trial. Analysis was performed with and without a 3.5% discount rate on future health. Smoking status had a large effect on optimal treatment choice. CMT was superior for nearly all never smoker example patients regardless of age, sex, and OAR doses. At a maximum, CMT produced a 1.095 (95% CI: 1.054-1.137) gain in undiscounted QALYs for a 20-year-old male never smoker with unilateral neck disease. In contrast, current smokers could substantially gain from chemotherapy-alone treatment. Again at a maximum, a 20-year-old male current smoker with bilateral neck and whole mediastinum involvement gained 3.500 (95% CI: 3.400 to 3.600) undiscounted QALYs with chemotherapy-alone treatment. Overall, CMT was more favorable the younger the patient, when future health discounting was included, and in never smokers.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021006254","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T16:23:20Z","timestamp":1643819000000},"page":"909-919","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":9,"title":["Informing radiotherapy decisions in stage I\/IIa Hodgkin lymphoma: modeling life expectancy using radiation dosimetry"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8440-1439","authenticated-orcid":false,"given":"David A.","family":"Jones","sequence":"first","affiliation":[{"name":"Health Economics Research Centre and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1521-088X","authenticated-orcid":false,"given":"Paolo","family":"Candio","sequence":"additional","affiliation":[{"name":"Health Economics Research Centre and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4835-4153","authenticated-orcid":false,"given":"Rebecca","family":"Shakir","sequence":"additional","affiliation":[{"name":"Clinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8575-2145","authenticated-orcid":false,"given":"Georgios","family":"Ntentas","sequence":"additional","affiliation":[{"name":"Clinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom;"},{"name":"Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, Department of Medical Physics, London, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Ramroth","sequence":"additional","affiliation":[{"name":"Clinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0239-7278","authenticated-orcid":false,"given":"Alastair M.","family":"Gray","sequence":"additional","affiliation":[{"name":"Health Economics Research Centre and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Cutter","sequence":"additional","affiliation":[{"name":"Clinical Trial Service Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom;"},{"name":"Oxford Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"key":"2022020216230213200_B1","doi-asserted-by":"crossref","first-page":"iv19","DOI":"10.1093\/annonc\/mdy080","article-title":"Hodgkin lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Eichenauer","year":"2018","journal-title":"Ann Oncol."},{"issue":"6","key":"2022020216230213200_B2","doi-asserted-by":"crossref","first-page":"755","DOI":"10.6004\/jnccn.2020.0026","article-title":"Hodgkin lymphoma, version 2.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Hoppe","year":"2020","journal-title":"J Natl Compr Canc Netw."},{"issue":"5","key":"2022020216230213200_B3","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/bjh.16232","article-title":"No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy","volume":"188","author":"Lagerl\u00f6f","year":"2020","journal-title":"Br J Haematol."},{"issue":"4","key":"2022020216230213200_B4","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jama.290.4.465","article-title":"Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease","volume":"290","author":"Travis","year":"2003","journal-title":"JAMA."},{"issue":"3","key":"2022020216230213200_B5","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/jnci\/94.3.182","article-title":"Lung cancer following chemotherapy and radiotherapy for Hodgkin\u2019s disease","volume":"94","author":"Travis","year":"2002","journal-title":"J Natl Cancer Inst."},{"issue":"2","key":"2022020216230213200_B6","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1667\/0033-7587(2003)159[0161:LCATFH]2.0.CO;2","article-title":"Lung cancer after treatment for Hodgkin\u2019s disease: focus on radiation effects","volume":"159","author":"Gilbert","year":"2003","journal-title":"Radiat Res."},{"issue":"3","key":"2022020216230213200_B7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma","volume":"34","author":"van Nimwegen","year":"2016","journal-title":"J Clin Oncol."},{"issue":"13","key":"2022020216230213200_B8","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/jnci\/djp147","article-title":"Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma","volume":"101","author":"De Bruin","year":"2009","journal-title":"J Natl Cancer Inst."},{"issue":"17","key":"2022020216230213200_B9","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med."},{"issue":"16","key":"2022020216230213200_B10","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 Trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol."},{"issue":"31","key":"2022020216230213200_B11","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1200\/JCO.19.00964","article-title":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin Lymphoma: final results of the international, randomized phase III HD16 Trial by the German Hodgkin Study Group","volume":"37","author":"Fuchs","year":"2019","journal-title":"J Clin Oncol."},{"issue":"6","key":"2022020216230213200_B12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1200\/JCO.2014.58.7543","article-title":"Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: analysis of the National Cancer Data Base","volume":"33","author":"Olszewski","year":"2015","journal-title":"J Clin Oncol."},{"issue":"35","key":"2022020216230213200_B13","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1200\/JCO.20.02668","article-title":"Continuum of care for Hodgkin lymphoma: impact of modern therapy on postacute morbidity and mortality","volume":"38","author":"Evens","year":"2020","journal-title":"J Clin Oncol."},{"issue":"6","key":"2022020216230213200_B14","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jval.2012.06.014","article-title":"State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force 3","volume":"15","author":"Siebert","year":"2012","journal-title":"Value Health."},{"issue":"1","key":"2022020216230213200_B15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1186\/s12913-019-4237-4","article-title":"PRIMEtime CE: a multistate life table model for estimating the cost-effectiveness of interventions affecting diet and physical activity","volume":"19","author":"Briggs","year":"2019","journal-title":"BMC Health Serv Res."},{"key":"2022020216230213200_B16","article-title":"Predicted risks of cardiovascular disease following chemotherapy and radiotherapy in the UK NCRI \u2018RAPID\u2019 Trial of PET-directed therapy for early-stage Hodgkin lymphoma","volume":"39","author":"Cutter","journal-title":"J Clin Oncol."},{"issue":"6","key":"2022020216230213200_B17","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1177\/0272989X11401031","article-title":"Catalogue of EQ-5D scores for the United Kingdom","volume":"31","author":"Sullivan","year":"2011","journal-title":"Med Decis Making."},{"issue":"2","key":"2022020216230213200_B18","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.radonc.2015.01.008","article-title":"A new method to estimate doses to the normal tissues after past extended and involved field radiotherapy for Hodgkin lymphoma","volume":"114","author":"Maraldo","year":"2015","journal-title":"Radiother Oncol."},{"issue":"2","key":"2022020216230213200_B19","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/bjh.15255","article-title":"Early-stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long-term patient outcomes","volume":"182","author":"Parsons","year":"2018","journal-title":"Br J Haematol."},{"issue":"2","key":"2022020216230213200_B20","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/bjh.15566","article-title":"Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom","volume":"184","author":"Br\u00f6ckelmann","year":"2019","journal-title":"Br J Haematol."},{"issue":"6","key":"2022020216230213200_B21","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1080\/10428194.2018.1540781","article-title":"Survivors\u2019 perspectives on risks and benefits of Hodgkin lymphoma treatment: results of a survey by the German Hodgkin Study Group","volume":"60","author":"Kreissl","year":"2019","journal-title":"Leuk Lymphoma."},{"issue":"1","key":"2022020216230213200_B22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijrobp.2015.01.013","article-title":"Minimizing late effects for patients with mediastinal Hodgkin lymphoma: deep inspiration breath-hold, IMRT, or both?","volume":"92","author":"Aznar","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"9","key":"2022020216230213200_B23","doi-asserted-by":"crossref","first-page":"e2013935","DOI":"10.1001\/jamanetworkopen.2020.13935","article-title":"Assessment of radiation doses delivered to organs at risk among patients with early-stage favorable Hodgkin lymphoma treated with contemporary radiation therapy","volume":"3","author":"Pinnix","year":"2020","journal-title":"JAMA Netw Open."},{"issue":"4","key":"2022020216230213200_B24","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv008","article-title":"Risk for valvular heart disease after treatment for Hodgkin lymphoma","volume":"107","author":"Cutter","year":"2015","journal-title":"JNCI: Journal of the National Cancer Institute."},{"issue":"16","key":"2022020216230213200_B25","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood-2016-09-740332","article-title":"Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines","volume":"129","author":"van Nimwegen","year":"2017","journal-title":"Blood."},{"issue":"1","key":"2022020216230213200_B26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1742-4682-8-27","article-title":"Site-specific dose-response relationships for cancer induction from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy","volume":"8","author":"Schneider","year":"2011","journal-title":"Theor Biol Med Model."},{"key":"2022020216230213200_B27","author":"National Research Council"},{"key":"2022020216230213200_B28","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.2307\/3583506","article-title":"Complication probability as assessed from dose-volume histograms","volume":"8","author":"Lyman","year":"1985","journal-title":"Radiat Res Suppl."},{"issue":"11","key":"2022020216230213200_B29","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N Engl J Med."},{"issue":"4","key":"2022020216230213200_B30","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.ijrobp.2015.11.046","article-title":"Radiation-related new primary solid cancers in the childhood cancer survivor study: comparative radiation dose response and modification of treatment effects","volume":"94","author":"Inskip","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"2022020216230213200_B31","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0360-3016(03)00073-7","article-title":"Radiation-induced second cancers: the impact of 3D-CRT and IMRT","volume":"56","author":"Hall","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"2022020216230213200_B32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijrobp.2017.09.039","article-title":"Intensity modulated radiation therapy and second cancer risk in adults","volume":"100","author":"Filippi","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"5","key":"2022020216230213200_B33","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.ijrobp.2021.03.005","article-title":"Mean heart dose is an inadequate surrogate for left anterior descending coronary artery dose and the risk of major adverse cardiac events in lung cancer radiation therapy","volume":"110","author":"Atkins","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"6","key":"2022020216230213200_B34","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.3324\/haematol.2014.119214","article-title":"Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway","volume":"100","author":"Smeland","year":"2015","journal-title":"Haematologica"},{"issue":"25","key":"2022020216230213200_B35","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med."},{"issue":"4","key":"2022020216230213200_B36","doi-asserted-by":"crossref","first-page":"e278","DOI":"10.1016\/S2352-3026(21)00029-6","article-title":"Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14)","volume":"8","author":"Gillessen","year":"2021","journal-title":"Lancet Haematol."},{"issue":"1","key":"2022020216230213200_B37","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/bloodadvances.2019001023","article-title":"Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I\/IIA Hodgkin lymphoma","volume":"4","author":"Illidge","year":"2020","journal-title":"Blood Adv."},{"issue":"5","key":"2022020216230213200_B38","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ijrobp.2020.03.019","article-title":"Involved site radiation therapy in adult lymphomas: an overview of International Lymphoma Radiation Oncology Group guidelines","volume":"107","author":"Wirth","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"16","key":"2022020216230213200_B39","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2018-03-837633","article-title":"Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines","volume":"132","author":"Dabaja","year":"2018","journal-title":"Blood."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/3\/909\/1866629\/advancesadv2021006254.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/3\/909\/1866629\/advancesadv2021006254.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T16:23:43Z","timestamp":1643819023000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/3\/909\/482914\/Informing-radiotherapy-decisions-in-stage-I-IIa"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,2,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021006254","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,2]]}}}